Analysts Set Benitec Biopharma Inc. (NASDAQ:BNTC) Target Price at $24.43

Shares of Benitec Biopharma Inc. (NASDAQ:BNTC) have been given an average rating of “Buy” by the nine brokerages that are presently covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $24.43.

BNTC has been the subject of a number of recent research reports. HC Wainwright restated a “buy” rating and set a $28.00 price target on shares of Benitec Biopharma in a research note on Friday. Guggenheim restated a “buy” rating and set a $17.00 price target on shares of Benitec Biopharma in a research report on Tuesday, December 3rd. Robert W. Baird assumed coverage on shares of Benitec Biopharma in a research report on Friday, December 13th. They set an “outperform” rating and a $30.00 price target for the company. Finally, Baird R W upgraded shares of Benitec Biopharma to a “strong-buy” rating in a research report on Thursday, December 12th.

Benitec Biopharma Trading Down 2.3 %

NASDAQ:BNTC opened at $11.30 on Tuesday. The company has a fifty day moving average of $11.29 and a 200-day moving average of $10.34. Benitec Biopharma has a twelve month low of $3.28 and a twelve month high of $13.29.

Benitec Biopharma (NASDAQ:BNTC) last announced its quarterly earnings results on Friday, February 14th. The biotechnology company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.19. On average, sell-side analysts predict that Benitec Biopharma will post -1.48 EPS for the current year.

Insider Transactions at Benitec Biopharma

In related news, Director Suvretta Capital Management, L purchased 42,000 shares of the stock in a transaction dated Tuesday, December 3rd. The stock was purchased at an average price of $9.60 per share, with a total value of $403,200.00. Following the transaction, the director now directly owns 7,957,365 shares in the company, valued at $76,390,704. This trade represents a 0.53 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.30% of the company’s stock.

Hedge Funds Weigh In On Benitec Biopharma

A number of hedge funds have recently bought and sold shares of the business. Northern Trust Corp raised its position in Benitec Biopharma by 54.2% in the 4th quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company’s stock worth $482,000 after buying an additional 13,425 shares during the last quarter. Geode Capital Management LLC raised its position in Benitec Biopharma by 31.3% in the 3rd quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company’s stock worth $772,000 after buying an additional 20,012 shares during the last quarter. Ameriprise Financial Inc. raised its position in Benitec Biopharma by 138.4% in the 4th quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company’s stock worth $448,000 after buying an additional 20,597 shares during the last quarter. Lion Point Capital LP grew its stake in shares of Benitec Biopharma by 59.0% during the 4th quarter. Lion Point Capital LP now owns 62,000 shares of the biotechnology company’s stock valued at $783,000 after purchasing an additional 23,000 shares during the period. Finally, Acuta Capital Partners LLC bought a new stake in shares of Benitec Biopharma during the 3rd quarter valued at about $274,000. Hedge funds and other institutional investors own 52.19% of the company’s stock.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.